Details of the Drug

General Information of Drug (ID: DMPDQ8T)

Drug Name
AB-103
Synonyms Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem
Indication
Disease Entry ICD 11 Status REF
Necrotizing soft tissue infection 1B71 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 281.25
Logarithm of the Partition Coefficient (xlogp) 0.8
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C12H16N3O3P
IUPAC Name
benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate
Canonical SMILES
C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3
InChI
InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17)
InChIKey
VFIUCBTYGKMLCM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
16111
CAS Number
1980-45-6
TTD ID
D04HQJ
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell-specific surface glycoprotein CD28 (CD28) TTQ13FT CD28_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02469857) Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)